Development of the coreHEM mental health patient‐reported outcome measure – A novel mental health outlook measure for people with haemophilia

2024-9-5

Determination of body composition by dual x‐ray absorptiometry in persons with haemophilia

2024-9-1

Issue Information

2024-9-1

Differences and similarities in patient‐reported outcomes among men and women with haemophilia

2024-8-27

Comprehensive laboratory assessment of lonoctocog alfa versus octocog alfa in severe haemophilia A

2024-8-20

Driving improvement of diagnosis and awareness of heavy menstrual bleeding in women among physicians

2024-8-20

Transitioning patients with severe haemophilia A from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: Real‐world clinical experience

2024-8-13

Factor V haemostatic diathesis impairing thrombin activation, membrane binding and circulating antigen level due to a novel compound heterozygous mutation, Leu1821Ser and Gly2192Cys

2024-8-8

Bioclinical features of haemophilia patients in Benin in 2023: Towards better care

2024-8-8

Sexual functioning in men with haemophilia: Data from the haemophilia in the Netherlands‐6 study

2024-8-7

Acute neuromuscular and perceptual responses to blood flow restriction exercise in adults with severe haemophilia: A pilot study

2024-8-4

Diagnosis and management of factor XI alloinhibitors in patients with congenital factor XI deficiency—A large single‐centre experience

2024-7-22

Multiyear, real‐world, retrospective cohort study using a patient‐centric approach to evaluate the burden of haemophilia B in the United States

2024-7-22

Application of the PECARN head trauma rule to patients with haemophilia in the paediatric emergency department: A 15‐year retrospective study

2024-7-21

Review of interventions and effectiveness for heavy menstrual bleeding in women with moderate and severe von Willebrand disease

2024-7-21

Efficacy of a 1:1 ratio VWF/FVIII concentrate in patients with von Willebrand disease

2024-7-15

Moving towards Normalization of haemostasis and health equity: Evolving treatment goals for haemophilia A

2024-7-10

A clinical practice guideline for primary care physiotherapy in patients with haemophilia

2024-7-10

Recombinant FVIII replacement products for haemophilia A: An updated valuation by indirect comparison measuring area under the curve

2024-7-9

Valoctocogene roxaparvovec gene therapy provides durable haemostatic control for up to 7 years for haemophilia A

2024-7-8

Issue Information

2024-7-1

Real world management of individuals with severe FXI deficiency and its impact on clinical outcomes: Experience from a haemophilia treatment centre

2024-7-1

Acquired haemophilia A in Finland: A nationwide study of incidence, treatment and outcomes

2024-6-28

Minimal interference of concizumab with standard clinical coagulation laboratory assays – An in vitro study

2024-6-25

Identifying hemophilia B carriers: Utility of aPTT, factor IX levels and ratios of factor IX to other Vitamin K dependent factors

2024-6-24

A qualitative study on the perioperative experiences and demands of haemophilic arthropathy patients undergoing total joint replacement

2024-6-24

Emicizumab plasma levels after accelerated saturation in acquired haemophilia A

2024-6-24

Accuracy and clinical role of digital templating for total knee arthroplasty performed on haemophilic knees

2024-6-20

Real‐world experience of rIX‐FP prophylaxis at dosing intervals of 14 days or more in adult patients with haemophilia B in Italy – Results from IDEAL Part B

2024-6-20

A case of bruising and joint hypermobility: The need to consider genetic testing for platelet disorders

2024-6-16

Reduced doses of emicizumab achieve good efficacy: Results from a national‐wide multicentre real‐world study in China

2024-6-9

Comparison of the kinematic analysis of indoor and outdoor gait in people with haemophilia and total knee replacement

2024-6-9

Evaluation of one‐stage and chromogenic assays for the laboratory measurement of factor VIII activity following valoctocogene roxaparvovec infusion

2024-6-6

Effects of resistance training on muscle strength in adults with haemophilia: A systematic review and meta‐analysis

2024-6-6

Low bleeding rates after intramuscular Covid‐19 vaccination in patients with haemophilia and von Willebrand disease: Outcome data from the Swedish haemophilia registry

2024-6-6

Functional clinical motor performance tests to assess potential fall risks in patients with haemophilia: A case‐control study

2024-6-4

Humanistic burden of haemophilia A without inhibitors: A cross‐sectional analysis of the HemoLIFE study

2024-6-2

Oral surgery in people with inherited bleeding disorder: A retrospective study

2024-6-2

Self‐conducted sonographic monitoring of the knee in patients with haemophilia—A feasibility study

2024-6-2

Limited value of testing for factor XIII and α2‐antiplasmin deficiency in patients with a bleeding disorder of unknown cause

2024-5-29

The relevance of MRI findings in joints of persons with haemophilia: Insights from the last decade

2024-5-29

Association between cognitive impairment and functional limitations in everyday life in patients with haemophilia in Hong Kong

2024-5-28

Treatment of thrombotic cardiovascular diseases in people with haemophilia: A Japanese consensus study

2024-5-23

Inherited coagulation factor VII deficiency in Taiwan: Two novel <i>F7</i> variants with relevant regional features in 33 patients

2024-5-23

Alleviated bleeding phenotypes in a child with severe haemophilia A and thalassemia disease

2024-5-23

Heterozygous large deletion mimicking homozygous substitution in <i>MCFD2</i> in a patient with combined Factor V and Factor VIII deficiency

2024-5-19

Retrospective chart review of GI bleeding in people with von Willebrand disease

2024-5-15

Spectrum, clinical characteristics and outcome of von Willebrand disease in Oman

2024-5-13